Skip to main content
88 search results for:

Neuro-oncology 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-10-2023 | Toxicities | Teaser

    Looking for coverage of ESMO 2023?

    There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

  2. 29-09-2023 | Adverse events | News | Article

    Trial adds to evidence for risk-based thromboprophylaxis in people with cancer

    The approach “reduced thromboembolism with a desirable number needed to treat, without safety concerns, and with reduced mortality,” say Marliese Alexander (Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia) and team in JAMA Oncology .

  3. 04-07-2023 | Non-small-cell lung cancer | News | Article

    Adagrasib shows intracranial efficacy in KRYSTAL-1 trial

    The researchers say in the Journal of Clinical Oncology that these are “the first prospective data for a KRAS G12C inhibitor” in this patient subgroup.

  4. 17-03-2023 | COVID-19 | News | Article

    Vaccination ‘protective’ against COVID-19 sequelae in people with cancer

    By contrast, there was no significant difference in the prevalence of weight loss, neurologic sequelae, or other sequelae by vaccination status, report Alessio Cortellini, from Imperial College London in the UK, and colleagues in The Lancet Oncology .

  5. 18-11-2022 | Breast cancer | News | Article

    Novel nonhormonal agent shows promise for hot flashes, night sweats in patients with breast cancer

    Finally, the safety analysis showed that “[t]reatment with Q-122 was well tolerated, and the majority of adverse events were mild or moderate in severity,” say Amanda Vrselja, from QUE Oncology in Melbourne, Victoria, Australia, and co-investigators.

  6. 16-11-2022 | Non-small-cell lung cancer | News | Article

    Telisotuzumab vedotin plus erlotinib may offer novel advanced NSCLC approach

    The majority (69%) had previously received at least three lines of treatment and 83% had been given a first- or second-generation EGFR–TKI, while 44% had received a third-generation agent as their last therapy, the team reports in the Journal of Clinical Oncology .

  7. 25-10-2022 | Immunotherapy | News | Article
    guidelinesWatch

    ESMO issues updated recommendations for management of immunotherapy toxicities

    The document is published in the Annals of Oncology and supersedes the previous version from 2017.

  8. 03-08-2022 | Adverse events | News | Article

    Hearing loss, tinnitus not uncommon in cancer survivors

    Noting that “a significant percentage of survivors are underestimating the occurrence of hearing loss” and that “these auditory deficits are not reversible,” Miaskowski and colleagues stress the need for oncology clinicians “to assess for hearing loss prior to and during chemotherapy and make appropriate referrals for an audiogram and follow-up.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group BMJ Support Palliat Care 2022; doi:10.1136/spcare-2022-003684

  9. 27-07-2022 | Breast cancer | News | Article

    Oral paclitaxel plus encequidar tops intravenous paclitaxel for metastatic breast cancer response

    The researchers explain in the Journal of Clinical Oncology that intravenous paclitaxel “is complicated by neuropathy and requires premedication to prevent hypersensitivity-type reactions,” but the taxane “is poorly absorbed orally.”

  10. 05-01-2022 | Prostate cancer | News | Article

    HRQoL data reported for ENZAMET trial of enzalutamide in metastatic HSPC

    The current report, published in the Journal of Clinical Oncology , focuses on the prespecified secondary endpoint of HRQoL, which was evaluated in 1042 of the 1125 trial participants.

  11. 02-11-2021 | Immunotherapy | News | Article
    guidelinesWatch

    ASCO updates guidelines for managing immune-related adverse events

    Writing in the Journal of Clinical Oncology , the guideline authors say: “With the increasing use of immunotherapy in cancer treatment regimens, it is imperative that clinicians be knowledgeable about the symptoms associated with these agents, how best to monitor them, and their recommended management.”

  12. 15-10-2021 | Chemotherapy | Adis Journal Club | Article
    Oncology and Therapy

    Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

    An evidence base for novel targets and both pharmacological and non-pharmacological treatments is beginning to emerge and has been recognised recently in publications by the American Society of Clinical Oncology and analgesic trial design expert groups such as ACTTION.

  13. 04-10-2021 | Breast cancer | News | Article

    Toxicity Index, PRO data shed light on early endocrine therapy discontinuations

    Writing in the Journal of Clinical Oncology , Henry et al conclude that their study “identified both anticipated and unanticipated toxicities associated with treatment discontinuation.”

  14. 22-06-2021 | ASCO 2021 | Conference coverage | Article

    COVID-19: Remote patient monitoring proves effective for outpatient management

    Daly also highlighted that 92% of respondents agreed or strongly agreed that they would recommend the program to other patients, while 7% disagreed or strongly disagreed with the statement, which gave a “high” net promoter score of 85%.

  15. 06-06-2021 | ASCO 2021 | Conference coverage | Article

    Immunotherapy plus chemo may be preferable for advanced NSCLC with PD-L1 score of 1–49%

    “Although the overall survival outcomes we have presented should reflect the composite net benefit of drug efficacy and safety, these results are not prescriptive and not intended to regulate the practice of oncology,” he continued.

  16. 17-05-2021 | Non-small-cell lung cancer | News | Article

    Nab-paclitaxel offers alternative to docetaxel in pretreated advanced NSCLC

    Okamoto and co-authors report in the Journal of Thoracic Oncology that both groups received a median of four treatment cycles but there were fewer dose reductions with nab-paclitaxel than with docetaxel (27.3 vs 53.4%).

  17. 05-11-2020 | COVID-19 | News | Article

    OncCOVID model predicts impact of delaying cancer treatment during pandemic

    As reported in JAMA Oncology , Schipper and team tested the model using data for 5,436,896 individuals in the National Cancer Database.

  18. 13-10-2020 | Breast cancer | News | Article

    Sacituzumab govitecan shows promise for HR+, HER2– metastatic breast cancer

    Kalinsky and co-authors report in the Annals of Oncology that the treatment responses were “durable,” with a median response duration of 8.7 months and a median progression-free survival (PFS) of 5.5 months.

  19. 23-07-2020 | Lung cancer | News | Article
    News in brief

    Lung cancer COVID-19 guidance available

    The second guidance is reported in the Journal of Thoracic Oncology by Chandra Belani, from Penn State Cancer Institute in Hershey, USA, and co-workers.

  20. 16-07-2020 | Lung cancer | News | Article

    Atypical skin signs apparent in lung cancer patients with COVID-19

    Two case studies reported in the Journal of Thoracic Oncology show that lung cancer patients receiving treatment with PD-1 inhibitors can present with atypical and severe skin manifestations when infected with SARS-CoV-2.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.